Baxter, Biomérieux ink acute kidney injury biomarker dev deal

Baxter, Biomérieux ink acute kidney injury biomarker dev deal

Source: 
Mass Device
snippet: 

Baxter (NYSE:BAX) said today that it inked a partnership deal with Biomérieux looking to develop biomarkers to identify acute kidney injury.